\-\ Texto\\:\\ \ \(0\)\
\-\ sub\\-mandibular\\ and\\ cervical\\ regions\\ of\\ neck\\ enlarged\\ bilateraly\\,\\ with\\ left\\ greater\\ than\\ right\\.\\ \\ masses\\ were\\ firm\\,\\ mobile\\ and\\ non\\-tender\\.\\ no\\ changes\\ in\\ the\\ skin\\ overlying\\ the\\ masses\\.\\ \\ ears\\/eyes\\/nose\\/oropharynx\\ normal\\.\\ \\ lungs\\ clear\\ bilateraly\\.\\ \\ cardiovascular\\ exam\\ was\\ normal\\.\ \(0\)\
\-\ left\\ neck\\ dissection\\ for\\ debulking\\ of\\ mass\\.\\ \\ po\\ steroids\\ for\\ respiratory\\ symptoms\\.\ \(0\)\
\-\ significant\\ bilateral\\ neck\\ adenopathy\\.\\ confluent\\ left\\ parotid\\ and\\ periparotid\\ nodal\\ mass\\ with\\ largest\\ single\\ node\\ measuring\\ 2\\.7cm\\ x\\ 1\\.9cm\\.\\ \\ numerous\\ other\\ left\\ level\\ ii\\ and\\ iii\\ nodes\\ with\\ largest\\ measuring\\ 3\\.6cm\\ x\\ 2\\.1cm\\.\\ \\ mediastinal\\ and\\ bihilar\\ adenopathy\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ reactive\\ lymphadenopathy\\ \\(fungal\\,\\ etc\\.\\)\ \(0\)\
\-\ \\â\\€\\¢\\ catscratch\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ carcinoma\ \(1\)\
\-\ 32\\ year\\ old\\ woman\\ with\\ a\\ 2\\ year\\ history\\ of\\ slowly\\ growing\\ lump\\ on\\ neck\\ along\\ and\\ progressive\\ shortness\\ of\\ breath\\.\\ \\ no\\ history\\ of\\ fevers\\,\\ weight\\ loss\\ or\\ recent\\ illness\\.\\ \\ patient\\ had\\ recently\\ undergone\\ dental\\ procedure\\ around\\ time\\ the\\ lump\\ was\\ first\\ noted\\.\ \(0\)\
\-\ sarciodosis\\ is\\ a\\ systemic\\ multisystem\\ granulomatous\\ disease\\ characterized\\ by\\ a\\ variable\\ clinical\\ presentation\\ and\\ course\\.\\ \\ cutaneous\\ lesions\\ are\\ present\\ in\\ about\\ one\\ fourth\\ of\\ patients\\.\\ although\\ any\\ organ\\ can\\ be\\ affected\\,\\ 90\\%\\ of\\ patients\\ demonstrate\\ thoracic\\ involvement\\ with\\ decreased\\ diffusion\\ capacity\\ being\\ the\\ most\\ common\\ abnormality\\ found\\ on\\ pulmonary\\ function\\ testing\\.\\ \\ there\\ is\\ a\\ strong\\ association\\ between\\ subcutaneous\\ sarciodosis\\ and\\ bilateral\\ hilar\\ lymphadenopathy\\ \\(72\\.7\\%\\)\\.\\ sarciodosis\\ is\\ a\\ diagnosis\\ of\\ exclusion\\ supported\\ by\\ three\\ elements\\:\\ 1\\.\\ compatible\\ clinical\\ and\\ radiologic\\ findings\\,\\ 2\\.\\ tissue\\ biopsy\\ specimen\\ that\\ reveals\\ noncaseating\\ epithelioid\\ granulomas\\,\\ and\\ 3\\.\\ absence\\ of\\ known\\ granulomagenic\\ agents\\.\\ \ \(0\)\
\-\ etiology\ \(199\)\
\-\ a\\ large\\ multi\\ centered\\ study\\ called\\ a\\ case\\ control\\ etiologic\\ study\\ of\\ sarciodosis\\ \\(access\\)\\ showed\\ that\\ environmental\\ factors\\ such\\ as\\ mold\\,\\ mildew\\,\\ must\\ odors\\ and\\ pesticides\\ were\\ associated\\ with\\ a\\ modestly\\ increased\\ risk\\ \\(or\\~1\\.5\\)\\ of\\ developing\\ sarciodosis\\.\\ genetics\\ and\\ host\\ factors\\ also\\ are\\ involved\\ in\\ the\\ pathogenesis\\ of\\ sarciodosis\\.\\ \\ in\\ the\\ us\\,\\ blacks\\ are\\ more\\ frequently\\ affected\\ and\\ the\\ access\\ trial\\ showed\\ that\\ affected\\ patients\\ were\\ five\\ times\\ more\\ likely\\ than\\ controls\\ to\\ report\\ a\\ sibling\\ with\\ the\\ disease\\.\\ \\ further\\,\\ recent\\ studies\\ have\\ identified\\ specific\\ genes\\ associated\\ with\\ sarciodosis\\.\\ \\ a\\ single\\-nucleotide\\ polymorphism\\ on\\ the\\ btnl2\\ gene\\ may\\ influence\\ t\\-lymphocyte\\ activation\\ and\\ regulation\\ and\\ make\\ people\\ carrying\\ this\\ polymorphism\\ more\\ susceptible\\ to\\ sarciodosis\\.\\ \\ a\\ second\\ gene\\ associated\\ with\\ sarciodosis\\ is\\ annexin\\ a11\\ on\\ chromosome\\ 10q22\\.3\\ responsible\\ for\\ calcium\\ signaling\\,\\ cell\\ division\\ and\\ apoptosis\\.\\ \\ \ \(0\)\
\-\ deficits\\ of\\ this\\ gene\\ have\\ been\\ associated\\ with\\ sarciodosis\\.\\ \\ further\\,\\ hla\\ haplotypes\\ and\\ t\\-cell\\ receptor\\ expression\\ play\\ an\\ intricate\\ role\\ in\\ the\\ development\\ of\\ the\\ disease\\.\ \(0\)\
\-\ biomarker\\ screening\ \(0\)\
\-\ in\\ an\\ attempt\\ to\\ aid\\ in\\ diagnosis\\ of\\ sarciodosis\\,\\ investigators\\ continue\\ to\\ search\\ for\\ potential\\ biomarkers\\ in\\ disease\\ activity\\.\\ chitotriosidase\\ is\\ an\\ enzyme\\ expressed\\ by\\ activated\\ macrophages\\ and\\ bargagli\\ et\\ al\\.\\ found\\ elevated\\ levels\\ of\\ this\\ enzyme\\ in\\ patients\\ with\\ sarciodosis\\,\\ with\\ \\>90\\%\\ exhibiting\\ elevated\\ levels\\ of\\ the\\ marker\\.\\ \\ a\\ second\\ marker\\ il\\-2\\,\\ a\\ cytokine\\ that\\ induces\\ t\\-cell\\ proliferation\\ and\\ activation\\ is\\ elevated\\ in\\ serum\\ of\\ patients\\ with\\ sarciodosis\\ and\\ may\\ have\\ prognostic\\ value\\.\\ \\ \ \(0\)\
\-\ diagnosis\ \(1295\)\
\-\ diagnosis\\ of\\ sarciodosis\\ is\\ best\\ supported\\ by\\ a\\ combination\\ of\\ radiographic\\ evidence\\ of\\ lymphadenopathy\\ and\\ tissue\\ specimens\\ that\\ show\\ noncaseating\\ granulomas\\.\\ \\ endobronchial\\ ultrasound\\ guided\\ transbronchial\\ needle\\ aspiration\\ when\\ compared\\ to\\ non\\-guided\\ transbronchial\\ needle\\ aspiration\\ had\\ a\\ diagnosis\\ yield\\ of\\ 83\\.3\\%\\ compared\\ to\\ 53\\.8\\%\\.\\ \\ \ \(0\)\
\-\ treatment\ \(1387\)\
\-\ therapy\\ for\\ patients\\ with\\ chronic\\ sarciodosis\\ requires\\ prolonged\\ treatment\\ often\\ with\\ steroids\\ which\\ cause\\ systemic\\ side\\ effects\\.\\ \\ tnf\\ inhibitors\\ have\\ been\\ investigated\\ for\\ the\\ treatment\\,\\ but\\ a\\ study\\ by\\ utz\\ et\\ al\\,\\ found\\ treatment\\ failure\\ in\\ nearly\\ 65\\%\\ of\\ participants\\.\\ \\ a\\ new\\ tnf\\-alpha\\ antagonist\\ ustekinumab\\,\\ approved\\ for\\ dosing\\ in\\ patients\\ with\\ ra\\,\\ psoriatic\\ arthritis\\,\\ and\\ ankylosing\\ spondylitis\\;\\ is\\ currently\\ being\\ tested\\ for\\ its\\ efficacy\\ in\\ treatment\\ of\\ sarciodosis\\ with\\ completion\\ of\\ the\\ study\\ anticipated\\ in\\ july\\ 2011\\.\\ \\ surgical\\ indication\\ for\\ patients\\ with\\ sarciodosis\\ remains\\ controversial\\.\\ \\ surgery\\ has\\ potential\\ to\\ reduce\\ symptoms\\ and\\ decrease\\ need\\ for\\ oral\\ steroids\\,\\ but\\ does\\ not\\ eradicate\\ or\\ prevent\\ recurrence\\ of\\ disease\\.\\ \\ corticosteroids\\ remain\\ the\\ cornerstone\\ for\\ treatment\\,\\ but\\ care\\ must\\ be\\ taken\\ to\\ assess\\ for\\ potential\\ adverse\\ effects\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarciodosis\\:\\ 0\\.7184879199433916\ \(0\)\
\-\ of\\:\\ 0\\.13446749429446106\ \(0\)\
\-\ and\\:\\ 0\\.1256031341481512\ \(0\)\
\-\ patients\\:\\ 0\\.11893719664747683\ \(0\)\
\-\ for\\:\\ 0\\.09612119179215817\ \(0\)\
\-\ with\\:\\ 0\\.09314850363941089\ \(0\)\
\-\ gene\\:\\ 0\\.09284631703573847\ \(0\)\
\-\ in\\:\\ 0\\.09204171850454224\ \(0\)\
\-\ polymorphism\\:\\ 0\\.08452799058157548\ \(0\)\
\-\ the\\:\\ 0\\.079099910653772\ \(0\)\
\-\ bilateraly\\:\\ 0\\.07810538579320746\ \(0\)\
\-\ noncaseating\\:\\ 0\\.0760377688694737\ \(0\)\
\-\ transbronchial\\:\\ 0\\.0760377688694737\ \(0\)\
\-\ treatment\\:\\ 0\\.07553411976996703\ \(0\)\
\-\ tnf\\:\\ 0\\.07434840283506003\ \(0\)\
\-\ activation\\:\\ 0\\.07168278100483944\ \(0\)\
\-\ potential\\:\\ 0\\.07084446757712352\ \(0\)\
\-\ enzyme\\:\\ 0\\.07059141987691259\ \(0\)\
\-\ study\\:\\ 0\\.07050206968366632\ \(0\)\
\-\ steroids\\:\\ 0\\.06965581283818657\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06850022855823226\ \(0\)\
\-\ disease\\:\\ 0\\.06656100833310154\ \(0\)\
\-\ affected\\:\\ 0\\.06520899313990237\ \(0\)\
\-\ neck\\:\\ 0\\.0646667590412819\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.06409649634557933\ \(0\)\
\-\ supported\\:\\ 0\\.06189754469049231\ \(0\)\
\-\ marker\\:\\ 0\\.06007485462815174\ \(0\)\
\-\ granulomas\\:\\ 0\\.0594355763345902\ \(0\)\
\-\ access\\:\\ 0\\.05913175042433756\ \(0\)\
\-\ is\\:\\ 0\\.0578997205830196\ \(0\)\
\-\ that\\:\\ 0\\.05734362802297671\ \(0\)\
\-\ by\\:\\ 0\\.05611413503933458\ \(0\)\
\-\ associated\\:\\ 0\\.055717979792249905\ \(0\)\
\-\ lump\\:\\ 0\\.055275666413743055\ \(0\)\
\-\ effects\\:\\ 0\\.05488953303983208\ \(0\)\
\-\ elevated\\:\\ 0\\.05404879218302787\ \(0\)\
\-\ largest\\:\\ 0\\.05381920679058203\ \(0\)\
\-\ to\\:\\ 0\\.05285542199447073\ \(0\)\
\-\ have\\:\\ 0\\.05280877990773773\ \(0\)\
\-\ guided\\:\\ 0\\.05185322737671665\ \(0\)\
\-\ found\\:\\ 0\\.05130020407392983\ \(0\)\
\-\ needle\\:\\ 0\\.04905233511375625\ \(0\)\
\-\ systemic\\:\\ 0\\.04690449379210024\ \(0\)\
\-\ aspiration\\:\\ 0\\.04621211586853404\ \(0\)\
\-\ cell\\:\\ 0\\.04535396119531205\ \(0\)\
\-\ must\\:\\ 0\\.045295352155608815\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.044773193730554675\ \(0\)\
\-\ factors\\:\\ 0\\.044709945293316615\ \(0\)\
\-\ adenopathy\\:\\ 0\\.044461182431008446\ \(0\)\
\-\ more\\:\\ 0\\.04353526199587837\ \(0\)\
\-\ compared\\:\\ 0\\.04273099756371956\ \(0\)\
\-\ periparotid\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ granulomagenic\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ mold\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ mildew\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ odors\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ modestly\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ btnl2\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ annexin\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ a11\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ haplotypes\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ intricate\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ biomarker\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ chitotriosidase\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ bargagli\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ cytokine\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ utz\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ ustekinumab\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ eradicate\\:\\ 0\\.04226399529078774\ \(0\)\
\-\ 90\\:\\ 0\\.042235378893219884\ \(0\)\
\-\ al\\:\\ 0\\.04199716885711376\ \(0\)\
\-\ levels\\:\\ 0\\.0419035735150707\ \(0\)\
\-\ et\\:\\ 0\\.04140504516953449\ \(0\)\
\-\ measuring\\:\\ 0\\.040890142704191605\ \(0\)\
\-\ were\\:\\ 0\\.04086848527058416\ \(0\)\
\-\ single\\:\\ 0\\.04064303845820894\ \(0\)\
\-\ bihilar\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ catscratch\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ pesticides\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ biomarkers\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ participants\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ antagonist\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ cornerstone\\:\\ 0\\.040385503811714026\ \(0\)\
\-\ second\\:\\ 0\\.039569757062999304\ \(0\)\
\-\ but\\:\\ 0\\.039205941204352446\ \(0\)\
\-\ multisystem\\:\\ 0\\.03905269289660373\ \(0\)\
\-\ controls\\:\\ 0\\.03905269289660373\ \(0\)\
\-\ signaling\\:\\ 0\\.03905269289660373\ \(0\)\
\-\ environmental\\:\\ 0\\.03801888443473685\ \(0\)\
\-\ regulation\\:\\ 0\\.03801888443473685\ \(0\)\
\-\ apoptosis\\:\\ 0\\.03801888443473685\ \(0\)\
\-\ investigators\\:\\ 0\\.03801888443473685\ \(0\)\
\-\ activated\\:\\ 0\\.03801888443473685\ \(0\)\
\-\ etiologic\\:\\ 0\\.037174201417530015\ \(0\)\
\-\ induces\\:\\ 0\\.037174201417530015\ \(0\)\
\-\ being\\:\\ 0\\.036832027008337084\ \(0\)\
\-\ blacks\\:\\ 0\\.0364600321024439\ \(0\)\
\-\ influence\\:\\ 0\\.0364600321024439\ \(0\)\
\-\ investigated\\:\\ 0\\.0364600321024439\ \(0\)\
\-\ left\\:\\ 0\\.036060557773652226\ \(0\)\
\-\ masses\\:\\ 0\\.03598324151603609\ \(0\)\
\-\ genes\\:\\ 0\\.03584139050241972\ \(0\)\
\-\ approved\\:\\ 0\\.03584139050241972\ \(0\)\
\-\ anticipated\\:\\ 0\\.03584139050241972\ \(0\)\
\-\ recent\\:\\ 0\\.03578867562552631\ \(0\)\
\-\ epithelioid\\:\\ 0\\.03529570993845629\ \(0\)\
\-\ exhibiting\\:\\ 0\\.03529570993845629\ \(0\)\
\-\ dosing\\:\\ 0\\.03529570993845629\ \(0\)\
\-\ showed\\:\\ 0\\.035205724922314836\ \(0\)\
\-\ sibling\\:\\ 0\\.034807582040552836\ \(0\)\
\-\ expressed\\:\\ 0\\.034807582040552836\ \(0\)\
\-\ further\\:\\ 0\\.03442589353076768\ \(0\)\
\-\ carrying\\:\\ 0\\.03436601664552593\ \(0\)\
\-\ expression\\:\\ 0\\.03436601664552593\ \(0\)\
\-\ capacity\\:\\ 0\\.033962899023345997\ \(0\)\
\-\ host\\:\\ 0\\.033962899023345997\ \(0\)\
\-\ yield\\:\\ 0\\.033962899023345997\ \(0\)\
\-\ chromosome\\:\\ 0\\.033592066758571654\ \(0\)\
\-\ receptor\\:\\ 0\\.033592066758571654\ \(0\)\
\-\ inhibitors\\:\\ 0\\.033592066758571654\ \(0\)\
\-\ clinical\\:\\ 0\\.033497544952345484\ \(0\)\
\-\ susceptible\\:\\ 0\\.033248729708259886\ \(0\)\
\-\ hla\\:\\ 0\\.032929090561479114\ \(0\)\
\-\ macrophages\\:\\ 0\\.032929090561479114\ \(0\)\
\-\ adverse\\:\\ 0\\.032929090561479114\ \(0\)\
\-\ genetics\\:\\ 0\\.0326300881082357\ \(0\)\
\-\ division\\:\\ 0\\.0326300881082357\ \(0\)\
\-\ debulking\\:\\ 0\\.03234921847672635\ \(0\)\
\-\ endobronchial\\:\\ 0\\.03234921847672635\ \(0\)\
\-\ play\\:\\ 0\\.03208440754427228\ \(0\)\
\-\ specimens\\:\\ 0\\.03208440754427228\ \(0\)\
\-\ efficacy\\:\\ 0\\.03208440754427228\ \(0\)\
\-\ on\\:\\ 0\\.031926740237099474\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.03159627964636882\ \(0\)\
\-\ parotid\\:\\ 0\\.031370238229186165\ \(0\)\
\-\ exclusion\\:\\ 0\\.030948772345246154\ \(0\)\
\-\ prognostic\\:\\ 0\\.030948772345246154\ \(0\)\
\-\ completion\\:\\ 0\\.030948772345246154\ \(0\)\
\-\ been\\:\\ 0\\.030794409467330516\ \(0\)\
\-\ undergone\\:\\ 0\\.030751596629161985\ \(0\)\
\-\ people\\:\\ 0\\.030751596629161985\ \(0\)\
\-\ tested\\:\\ 0\\.030751596629161985\ \(0\)\
\-\ confluent\\:\\ 0\\.030562471184501932\ \(0\)\
\-\ nodal\\:\\ 0\\.030562471184501932\ \(0\)\
\-\ an\\:\\ 0\\.03031784213717302\ \(0\)\
\-\ responsible\\:\\ 0\\.030205916065198568\ \(0\)\
\-\ controversial\\:\\ 0\\.030205916065198568\ \(0\)\
\-\ are\\:\\ 0\\.030084579575538856\ \(0\)\
\-\ july\\:\\ 0\\.03003742731407587\ \(0\)\
\-\ than\\:\\ 0\\.02996247140460937\ \(0\)\
\-\ trial\\:\\ 0\\.02941878571405169\ \(0\)\
\-\ indication\\:\\ 0\\.02941878571405169\ \(0\)\
\-\ dental\\:\\ 0\\.029276222772268195\ \(0\)\
\-\ aid\\:\\ 0\\.029137916082542337\ \(0\)\
\-\ symptoms\\:\\ 0\\.028919720053750774\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.02862261549654621\ \(0\)\
\-\ ankylosing\\:\\ 0\\.028502272885313918\ \(0\)\
\-\ bilateral\\:\\ 0\\.02840667739373533\ \(0\)\
\-\ proliferation\\:\\ 0\\.028384977252184803\ \(0\)\
\-\ psoriatic\\:\\ 0\\.028384977252184803\ \(0\)\
\-\ specimen\\:\\ 0\\.028158935835002154\ \(0\)\
\-\ spondylitis\\:\\ 0\\.028158935835002154\ \(0\)\
\-\ role\\:\\ 0\\.02773746995106214\ \(0\)\
\-\ tissue\\:\\ 0\\.02772698088961774\ \(0\)\
\-\ agents\\:\\ 0\\.027637833206871527\ \(0\)\
\-\ or\\:\\ 0\\.027581406934844684\ \(0\)\
\-\ strong\\:\\ 0\\.02754029423497797\ \(0\)\
\-\ multi\\:\\ 0\\.02754029423497797\ \(0\)\
\-\ centered\\:\\ 0\\.02754029423497797\ \(0\)\
\-\ search\\:\\ 0\\.02754029423497797\ \(0\)\
\-\ cutaneous\\:\\ 0\\.02744476651991604\ \(0\)\
\-\ attempt\\:\\ 0\\.02725942460346862\ \(0\)\
\-\ this\\:\\ 0\\.027243326324579733\ \(0\)\
\-\ organ\\:\\ 0\\.027169461970203625\ \(0\)\
\-\ po\\:\\ 0\\.02708121301553737\ \(0\)\
\-\ value\\:\\ 0\\.026909603395291016\ \(0\)\
\-\ reduce\\:\\ 0\\.026909603395291016\ \(0\)\
\-\ remain\\:\\ 0\\.0267441240174725\ \(0\)\
\-\ cardiovascular\\:\\ 0\\.026663549290234134\ \(0\)\
\-\ may\\:\\ 0\\.0265987239805043\ \(0\)\
\-\ illness\\:\\ 0\\.02658435197642613\ \(0\)\
\-\ compatible\\:\\ 0\\.02642990667357954\ \(0\)\
\-\ nearly\\:\\ 0\\.026354572817984766\ \(0\)\
\-\ had\\:\\ 0\\.026334721504772302\ \(0\)\
\-\ elements\\:\\ 0\\.026207483319867674\ \(0\)\
\-\ ra\\:\\ 0\\.02613565350833674\ \(0\)\
\-\ mobile\\:\\ 0\\.026064920378084184\ \(0\)\
\-\ slowly\\:\\ 0\\.026064920378084184\ \(0\)\
\-\ etc\\:\\ 0\\.025995250944320945\ \(0\)\
\-\ growing\\:\\ 0\\.025926613688358326\ \(0\)\
\-\ continue\\:\\ 0\\.025926613688358326\ \(0\)\
\-\ variable\\:\\ 0\\.025661802755904257\ \(0\)\
\-\ make\\:\\ 0\\.025661802755904257\ \(0\)\
\-\ requires\\:\\ 0\\.025597899259461352\ \(0\)\
\-\ prolonged\\:\\ 0\\.025597899259461352\ \(0\)\
\-\ developing\\:\\ 0\\.02529097049112991\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.02517367485800079\ \(0\)\
\-\ remains\\:\\ 0\\.02517367485800079\ \(0\)\
\-\ called\\:\\ 0\\.024679759414011907\ \(0\)\
\-\ radiologic\\:\\ 0\\.024627994294037375\ \(0\)\
\-\ combination\\:\\ 0\\.024526167556878125\ \(0\)\
\-\ assess\\:\\ 0\\.024426530812687513\ \(0\)\
\-\ need\\:\\ 0\\.02432899184079396\ \(0\)\
\-\ characterized\\:\\ 0\\.02428098177345042\ \(0\)\
\-\ hilar\\:\\ 0\\.024233464125732025\ \(0\)\
\-\ prevent\\:\\ 0\\.024233464125732025\ \(0\)\
\-\ dissection\\:\\ 0\\.02400292253331562\ \(0\)\
\-\ firm\\:\\ 0\\.02395815957601961\ \(0\)\
\-\ five\\:\\ 0\\.02386991062135336\ \(0\)\
\-\ calcium\\:\\ 0\\.02386991062135336\ \(0\)\
\-\ association\\:\\ 0\\.02378331127683054\ \(0\)\
\-\ times\\:\\ 0\\.02378331127683054\ \(0\)\
\-\ testing\\:\\ 0\\.0237406111585369\ \(0\)\
\-\ fourth\\:\\ 0\\.023698301001107\ \(0\)\
\-\ serum\\:\\ 0\\.023698301001107\ \(0\)\
\-\ fungal\\:\\ 0\\.02365637374627981\ \(0\)\
\-\ granulomatous\\:\\ 0\\.023492359095011243\ \(0\)\
\-\ fevers\\:\\ 0\\.023333952894198495\ \(0\)\
\-\ recently\\:\\ 0\\.023069141961744425\ \(0\)\
\-\ iii\\:\\ 0\\.022818652308202365\ \(0\)\
\-\ node\\:\\ 0\\.022715311294174312\ \(0\)\
\-\ deficits\\:\\ 0\\.022715311294174312\ \(0\)\
\-\ decrease\\:\\ 0\\.022715311294174312\ \(0\)\
\-\ regions\\:\\ 0\\.022681370262965676\ \(0\)\
\-\ reactive\\:\\ 0\\.022681370262965676\ \(0\)\
\-\ 32\\:\\ 0\\.022647676077804407\ \(0\)\
\-\ 65\\:\\ 0\\.022614225174079846\ \(0\)\
\-\ control\\:\\ 0\\.02258101406384096\ \(0\)\
\-\ overlying\\:\\ 0\\.02251529764229612\ \(0\)\
\-\ nodes\\:\\ 0\\.022450500361720242\ \(0\)\
\-\ numerous\\:\\ 0\\.022323562831169517\ \(0\)\
\-\ diffusion\\:\\ 0\\.02226137491706019\ \(0\)\
\-\ report\\:\\ 0\\.02226137491706019\ \(0\)\
\-\ development\\:\\ 0\\.02184797331720832\ \(0\)\
\-\ recurrence\\:\\ 0\\.021819809522033287\ \(0\)\
\-\ frequently\\:\\ 0\\.021763990412603056\ \(0\)\
\-\ normal\\:\\ 0\\.02158068395403162\ \(0\)\
\-\ arthritis\\:\\ 0\\.021494558103168398\ \(0\)\
\-\ screening\\:\\ 0\\.021468457019827893\ \(0\)\
\-\ be\\:\\ 0\\.021441500128630823\ \(0\)\
\-\ function\\:\\ 0\\.021391024631770332\ \(0\)\
\-\ mediastinal\\:\\ 0\\.021340112800321807\ \(0\)\
\-\ etiology\\:\\ 0\\.02128975436930263\ \(0\)\
\-\ best\\:\\ 0\\.021264778944727034\ \(0\)\
\-\ shortness\\:\\ 0\\.021190650482670707\ \(0\)\
\-\ involved\\:\\ 0\\.021190650482670707\ \(0\)\
\-\ oral\\:\\ 0\\.021166202246311303\ \(0\)\
\-\ taken\\:\\ 0\\.021117689446609942\ \(0\)\
\-\ around\\:\\ 0\\.021093622223453505\ \(0\)\
\-\ procedure\\:\\ 0\\.021069679379266404\ \(0\)\
\-\ absence\\:\\ 0\\.021069679379266404\ \(0\)\
\-\ respiratory\\:\\ 0\\.02102216173154801\ \(0\)\
\-\ us\\:\\ 0\\.02102216173154801\ \(0\)\
\-\ ii\\:\\ 0\\.020836819815100594\ \(0\)\
\-\ currently\\:\\ 0\\.020301243791759654\ \(0\)\
\-\ progressive\\:\\ 0\\.020240944501866108\ \(0\)\
\-\ history\\:\\ 0\\.020193989708915287\ \(0\)\
\-\ mass\\:\\ 0\\.020189518847512373\ \(0\)\
\-\ reveals\\:\\ 0\\.020103225188374173\ \(0\)\
\-\ failure\\:\\ 0\\.02006461721462333\ \(0\)\
\-\ specific\\:\\ 0\\.020026328318683107\ \(0\)\
\-\ about\\:\\ 0\\.019784878531499652\ \(0\)\
\-\ thoracic\\:\\ 0\\.01974882441927884\ \(0\)\
\-\ skin\\:\\ 0\\.019659897888006057\ \(0\)\
\-\ radiographic\\:\\ 0\\.019607349914018354\ \(0\)\
\-\ its\\:\\ 0\\.019555391275527516\ \(0\)\
\-\ course\\:\\ 0\\.019521073118320038\ \(0\)\
\-\ lungs\\:\\ 0\\.019504008899990297\ \(0\)\
\-\ greater\\:\\ 0\\.019470067868781665\ \(0\)\
\-\ activity\\:\\ 0\\.01940292277989583\ \(0\)\
\-\ studies\\:\\ 0\\.019386287465653317\ \(0\)\
\-\ breath\\:\\ 0\\.019369711669656946\ \(0\)\
\-\ abnormality\\:\\ 0\\.019223139268480943\ \(0\)\
\-\ clear\\:\\ 0\\.019159455378609736\ \(0\)\
\-\ involvement\\:\\ 0\\.01912793872619122\ \(0\)\
\-\ cervical\\:\\ 0\\.01892814627463004\ \(0\)\
\-\ risk\\:\\ 0\\.018883238685162358\ \(0\)\
\-\ care\\:\\ 0\\.018883238685162358\ \(0\)\
\-\ identified\\:\\ 0\\.018736614737971533\ \(0\)\
\-\ biopsy\\:\\ 0\\.018525028652450114\ \(0\)\
\-\ weight\\:\\ 0\\.01842950093738818\ \(0\)\
\-\ was\\:\\ 0\\.018420782594106802\ \(0\)\
\-\ new\\:\\ 0\\.018283255708984383\ \(0\)\
\-\ does\\:\\ 0\\.01827018678624522\ \(0\)\
\-\ side\\:\\ 0\\.01825715462564388\ \(0\)\
\-\ presentation\\:\\ 0\\.0181925380964887\ \(0\)\
\-\ enlarged\\:\\ 0\\.018016264061009292\ \(0\)\
\-\ cause\\:\\ 0\\.018003926024319487\ \(0\)\
\-\ although\\:\\ 0\\.017991620758018044\ \(0\)\
\-\ first\\:\\ 0\\.017834557240894996\ \(0\)\
\-\ three\\:\\ 0\\.01774048436335134\ \(0\)\
\-\ along\\:\\ 0\\.01770569373649035\ \(0\)\
\-\ often\\:\\ 0\\.017244215253293376\ \(0\)\
\-\ no\\:\\ 0\\.017188116855696715\ \(0\)\
\-\ between\\:\\ 0\\.017171581043802456\ \(0\)\
\-\ known\\:\\ 0\\.017110216834920457\ \(0\)\
\-\ any\\:\\ 0\\.017079836856953162\ \(0\)\
\-\ such\\:\\ 0\\.01699978423824512\ \(0\)\
\-\ show\\:\\ 0\\.016777050875497114\ \(0\)\
\-\ decreased\\:\\ 0\\.016369995360994354\ \(0\)\
\-\ ultrasound\\:\\ 0\\.016301230758512603\ \(0\)\
\-\ year\\:\\ 0\\.016289128411336673\ \(0\)\
\-\ pulmonary\\:\\ 0\\.016109034775771157\ \(0\)\
\-\ loss\\:\\ 0\\.016100856609412975\ \(0\)\
\-\ changes\\:\\ 0\\.015971931976091543\ \(0\)\
\-\ level\\:\\ 0\\.015963992076909312\ \(0\)\
\-\ when\\:\\ 0\\.015963992076909312\ \(0\)\
\-\ carcinoma\\:\\ 0\\.015807986427136194\ \(0\)\
\-\ likely\\:\\ 0\\.015792670941985686\ \(0\)\
\-\ lymphoma\\:\\ 0\\.01573946197275226\ \(0\)\
\-\ chronic\\:\\ 0\\.01568685717356584\ \(0\)\
\-\ time\\:\\ 0\\.01566449383148405\ \(0\)\
\-\ significant\\:\\ 0\\.015258898043939399\ \(0\)\
\-\ therapy\\:\\ 0\\.015184553297013917\ \(0\)\
\-\ lesions\\:\\ 0\\.015177853469325866\ \(0\)\
\-\ one\\:\\ 0\\.01513122401707699\ \(0\)\
\-\ evidence\\:\\ 0\\.015000526209170762\ \(0\)\
\-\ common\\:\\ 0\\.014987656950787761\ \(0\)\
\-\ metastatic\\:\\ 0\\.014494391342306337\ \(0\)\
\-\ increased\\:\\ 0\\.014290961734975507\ \(0\)\
\-\ surgery\\:\\ 0\\.014208766852191478\ \(0\)\
\-\ noted\\:\\ 0\\.014012043769592981\ \(0\)\
\-\ can\\:\\ 0\\.013868534462769148\ \(0\)\
\-\ woman\\:\\ 0\\.013763746440728716\ \(0\)\
\-\ most\\:\\ 0\\.013753889139055026\ \(0\)\
\-\ demonstrate\\:\\ 0\\.013739142399690074\ \(0\)\
\-\ other\\:\\ 0\\.013724442450692598\ \(0\)\
\-\ present\\:\\ 0\\.013561023412021441\ \(0\)\
\-\ exam\\:\\ 0\\.013303827465334133\ \(0\)\
\-\ case\\:\\ 0\\.013277098948665897\ \(0\)\
\-\ large\\:\\ 0\\.013241699119978561\ \(0\)\
\-\ findings\\:\\ 0\\.01304323788172691\ \(0\)\
\-\ surgical\\:\\ 0\\.01284483054152474\ \(0\)\
\-\ also\\:\\ 0\\.012430935525618417\ \(0\)\
\-\ has\\:\\ 0\\.012071503192872783\ \(0\)\
\-\ which\\:\\ 0\\.012017037554103327\ \(0\)\
\-\ as\\:\\ 0\\.010617032857255808\ \(0\)\
\-\ there\\:\\ 0\\.010515586811273075\ \(0\)\
\-\ not\\:\\ 0\\.010433113627476117\ \(0\)\
\-\ right\\:\\ 0\\.00876194850864589\ \(0\)\
\-\ patient\\:\\ 0\\.00859567522424895\ \(0\)\
\-\ old\\:\\ 0\\.007821600948307035\ \(0\)\
